OLMA RSI Chart
Last 7 days
0.3%
Last 30 days
-11.1%
Last 90 days
-10.7%
Trailing 12 Months
115.1%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 28, 2024 | harmon cyrus | sold | -219,400 | 10.97 | -20,000 | - |
Mar 18, 2024 | zojwalla naseem | acquired | 66,719 | 4.87 | 13,700 | chief medical officer |
Mar 05, 2024 | rappaport andrew | sold | - | - | -481,014 | - |
Mar 05, 2024 | rappaport andrew | acquired | - | - | 385,965 | - |
Feb 29, 2024 | harmon cyrus | sold | -310,309 | 12.4124 | -25,000 | - |
Feb 01, 2024 | harmon cyrus | sold | -77,800 | 15.56 | -5,000 | - |
Jan 31, 2024 | harmon cyrus | sold | -305,750 | 12.23 | -25,000 | - |
Jan 25, 2024 | zojwalla naseem | acquired | 140,400 | 7.02 | 20,000 | chief medical officer |
Jan 12, 2024 | kovacs shane william charles | acquired | 351,000 | 7.02 | 50,000 | ch. operating & financial off. |
Dec 29, 2023 | harmon cyrus | sold | -334,500 | 13.38 | -25,000 | - |
Which funds bought or sold OLMA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -19.54 | -497,292 | 920,327 | -% |
Apr 25, 2024 | Lindbrook Capital, LLC | unchanged | - | -428 | 1,789 | -% |
Apr 25, 2024 | Zurcher Kantonalbank (Zurich Cantonalbank) | unchanged | - | -25,154 | 105,072 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | reduced | -88.45 | -237,000 | 24,000 | -% |
Apr 23, 2024 | AMALGAMATED BANK | reduced | -61.33 | -23,000 | 10,000 | -% |
Apr 22, 2024 | MetLife Investment Management, LLC | unchanged | - | 25,040 | 209,117 | -% |
Apr 22, 2024 | Vivo Capital, LLC | unchanged | - | -5,077,740 | 21,210,300 | 1.67% |
Apr 18, 2024 | WOLFF WIESE MAGANA LLC | new | - | 6,792 | 6,792 | 0.01% |
Apr 11, 2024 | Fortitude Family Office, LLC | unchanged | - | -865 | 3,611 | -% |
Apr 05, 2024 | CWM, LLC | unchanged | - | -2,000 | 12,000 | -% |
Unveiling Olema Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Olema Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Olema Pharmaceuticals Inc News
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -5.4% | 277 | 293 | 178 | 196 | 216 | 232 | 251 | 277 | 296 | 310 | 322 | 331 | 343 |
Current Assets | -5.5% | 267 | 282 | 172 | 189 | 209 | 225 | 243 | 270 | 291 | 308 | 321 | 330 | 342 |
Cash Equivalents | -41.6% | 69.00 | 117 | 35.00 | 41.00 | 24.00 | 27.00 | 25.00 | 22.00 | 14.00 | 26.00 | 50.00 | 48.00 | 339 |
Net PPE | -8.3% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | 30.5% | 23.00 | 18.00 | 16.00 | 21.00 | 18.00 | 14.00 | 14.00 | 12.00 | 11.00 | 9.00 | 8.00 | 5.00 | 5.00 |
Current Liabilities | 35.4% | 22.00 | 16.00 | 15.00 | 19.00 | 17.00 | 13.00 | 12.00 | 10.00 | 9.00 | 9.00 | 8.00 | 5.00 | 5.00 |
Shareholder's Equity | -7.7% | 254 | 275 | 162 | 175 | 198 | 218 | 236 | 265 | 285 | 301 | 314 | 326 | 338 |
Retained Earnings | -9.6% | -305 | -278 | -257 | -237 | -208 | -182 | -160 | -127 | -104 | -82.55 | -64.84 | -48.43 | -33.09 |
Additional Paid-In Capital | 0.9% | 559 | 554 | 419 | 413 | 408 | 403 | 399 | 394 | 389 | 383 | 379 | 374 | 371 |
Shares Outstanding | 0.7% | 55.00 | 55.00 | 41.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 39.00 | 39.00 | - |
Float | - | - | - | 245 | - | - | - | 120 | - | - | - | 715 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 18.8% | -18,476 | -22,744 | -22,116 | -20,391 | -19,711 | -17,992 | -26,459 | -17,903 | -18,603 | -12,098 | -8,905 | -11,084 | -9,013 | -7,536 | -1,181 | -2,136 | - |
Share Based Compensation | 6.0% | 4,351 | 4,105 | 4,170 | 4,630 | 4,861 | 4,275 | 4,728 | 4,965 | 4,627 | 4,157 | 3,921 | 3,208 | - | - | - | - | - |
Cashflow From Investing | -21.5% | -30,915 | -25,436 | 14,113 | 37,387 | 16,336 | 20,164 | 29,412 | 25,567 | 6,000 | -12,784 | 10,930 | -279,584 | -51.00 | 10.00 | -6.00 | -9.00 | - |
Cashflow From Financing | -99.6% | 523 | 130,629 | 2,043 | 220 | 273 | 106 | 64.00 | 33.00 | 818 | 57.00 | - | - | 219,789 | 84,874 | 23,754 | 29,986 | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 86,140 | $ 82,274 |
General and administrative | 18,821 | 24,714 |
Total operating expenses | 104,961 | 106,988 |
Loss from operations | (104,961) | (106,988) |
Other income (expense): | ||
Interest income | 8,325 | 2,228 |
Other expense | (19) | (27) |
Total other income | 8,306 | 2,201 |
Net loss | $ (96,655) | $ (104,787) |
Net loss per share, basic (in dollars per share) | $ (2.14) | $ (2.62) |
Net loss per share, diluted (in dollars per share) | $ (2.14) | $ (2.62) |
Weighted average shares used to compute net loss per share, basic (in shares) | 45,247,098 | 39,995,460 |
Weighted average shares used to compute net loss per share, diluted (in shares) | 45,247,098 | 39,995,460 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 68,539 | $ 23,702 |
Marketable securities | 193,268 | 180,719 |
Prepaid expenses and other current assets | 4,706 | 4,478 |
Total current assets | 266,513 | 208,899 |
Operating lease right-of-use assets | 2,291 | 2,495 |
Other assets and long-term deposits | 8,141 | 4,251 |
Total assets | 276,945 | 215,645 |
Current liabilities: | ||
Accounts payable | 2,698 | 374 |
Operating lease liabilities, current | 988 | 1,015 |
Other current liabilities | 17,935 | 15,160 |
Total current liabilities | 21,621 | 16,549 |
Operating lease liabilities, net of current portion | 1,429 | 1,550 |
Total liabilities | 23,050 | 18,099 |
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022. | ||
Common stock, $0.0001 par value; 490,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 55,097,118 and 40,601,648 shares issued as of December 31, 2023 and December 31, 2022, respectively; 54,992,784 and 40,287,097 shares outstanding as of December 31, 2023 and December 31, 2022, respectively. | 4 | 3 |
Additional paid-in capital | 559,176 | 408,333 |
Accumulated other comprehensive gain (loss) | 347 | (1,813) |
Accumulated deficit | (305,632) | (208,977) |
Total stockholders' equity | 253,895 | 197,546 |
Total liabilities and stockholders' equity | $ 276,945 | $ 215,645 |